Endocrinology

A new scientific statement from the AHA offers guidance to clinicians tasked with treating CAD in patients with type 2 diabetes.

A conversation on new AI software which can identify a five-fold greater rate of potential fractures.

Results of a new study dive deeper into the impact of preoperative metformin use in diabetics.

Endocrinologists make can a difference in COVID-19 by restricting their use of glucocorticoids.  According to an editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism, patients treated with glucocorticoids will be at higher risk for coronavirus disease 2019 (COVID-19), the infection caused by the novel coronavirus. 

Patrick Campbell sat down  with Paul Stewart, MD, Executive Dean of the Faculty of Medicine and Health at University of Leeds and editor in chief of the Journal of Clinical Endocrinology & Metabolism to discuss why endocrinologists are expressing additional concern for their patients during the COVID-19 outbreak.

Discussing the impact of the ongoing outbreak on endocrinology practices and endocrinologists with the Executive Dean of the Faculty of Medicine and Health at University of Leeds.

Discussing an editorial in the Journal of Clinical Endocrinology & Metabolism with journal editor in chief Paul Stewart, MD.

A new perspective from federal and institutional experts explains the cause of disease severity and mortality in older, cardiovascular-risk patients.

A new perspective from a team of Maryland-based cardiovascular clinicians sheds insight on an often forgotten facet of the inherent COVID-19 risk carried by patients with cardiovascular history: the decline in angiotensin-converting enzyme 2 (ACE2) expression associated with aging, and the response of care most common in such patients.

There is a growing understanding that obesity and non-alcoholic fatty liver disease are related.

Currently, guidelines call for liver biopsies to diagnose NASH disease in patients.

Bout moderate-to-vigorous physical activity does not increase as much in very poor fitness groups.

The findings can lead to more education on the risk of thyroid immune-related adverse event.

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

An analysis shows that patients find desiccated thyroid extract to be more effective and improve patient outcomes better than other therapies.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

African American and Hispanic patients use devices for type 1 diabetes less than Caucasian patients.

Study from ENDO 2020 assesses the effects of teprotumumab based on the age, gender, and smoking status of patients.

Appropriate monitoring and treatment of hypothyroidism is needed for individuals who work long hours.

New data from ENDO 2020 suggests the presence of erectile dysfunction and sexual symptoms was linked to increased risk of death.

Treating thyrotropin changes associated with aging adaptation could adversely alter key homeostatic compensations.

Glucagon-like receptor agonists did not reduce the rate of hospitalization for heart failure as much as SGLT2 inhibitors did.

Patients with fractures closer to the center of the body had a 1.5- to four-fold greater risk of death over 2 years of follow-up.

The location of a broken bone can significantly impact the long-term health outcomes of older individuals, according to the new research findings to be presented at the Endocrine Society (ENDO) 2020 Annual Scientific Sessions.

An AI tool identified a near five-fold higher amount of potential fractures than the manual method.

An artificial intelligence tool trained to pinpoint patients with broken bones who are also at risk for osteoporosis outperforms radiologists who manually read the reports, a new study has found.

For every 1% higher baseline A1C, there was a 0.06 lower standardized CASI z-score.

A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.